Clinical Trials Browser

Carcinoma, Hepatocellular × dostarlimab × 90 days × Clear all

NCT03680508 2026-04-02

TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular